These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 2122647)

  • 21. [Treatment of pharmacotoxic psychoses with clopenthixol in patients with Parkinson's disease (author's transl)].
    Danielczyk W
    Wien Klin Wochenschr; 1981 Aug; 93(15):500-1. PubMed ID: 7303692
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Involvement of serotonin in clinical features of Parkinson's disease and complications of L-DOPA therapy.
    Melamed E; Zoldan J; Friedberg G; Ziv I; Weizmann A
    Adv Neurol; 1996; 69():545-50. PubMed ID: 8615179
    [No Abstract]   [Full Text] [Related]  

  • 23. Therapeutic dilemma: psychosis and Parkinson's disease.
    Damecour CL; Turcotte JR
    Can J Psychiatry; 1995 Dec; 40(10):640-1. PubMed ID: 8681265
    [No Abstract]   [Full Text] [Related]  

  • 24. Treatment of drug-induced psychosis in Parkinson's disease with clozapine.
    Greene P; Cote L; Fahn S
    Adv Neurol; 1993; 60():703-6. PubMed ID: 8420214
    [No Abstract]   [Full Text] [Related]  

  • 25. Managing psychosis in patients with Parkinson's disease.
    Cummings JL
    N Engl J Med; 1999 Mar; 340(10):801-3. PubMed ID: 10072418
    [No Abstract]   [Full Text] [Related]  

  • 26. Parkinson's disease in 1984: an update.
    Lang AE; Blair RD
    Can Med Assoc J; 1984 Nov; 131(9):1031-7. PubMed ID: 6388779
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug treatment of Parkinson's disease.
    Callaghan N
    Ir Med J; 1983 Aug; 76(8):364-6. PubMed ID: 6618850
    [No Abstract]   [Full Text] [Related]  

  • 28. [Dopamine-receptor stimulants in the treatment of Parkinson's disease (author's transl)].
    Ringwald E; Hirt D; Markstein R; Vigouret JM
    Nervenarzt; 1982 Feb; 53(2):67-71. PubMed ID: 7063089
    [No Abstract]   [Full Text] [Related]  

  • 29. Short-term levodopa test assessed by movement time accurately predicts dopaminergic responsiveness in Parkinson's disease.
    Zappia M; Montesanti R; Colao R; Branca D; Nicoletti G; Aguglia U; Quattrone A
    Mov Disord; 1997 Jan; 12(1):103-6. PubMed ID: 8990062
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Limitations of current Parkinson's disease therapy.
    Rascol O; Payoux P; Ory F; Ferreira JJ; Brefel-Courbon C; Montastruc JL
    Ann Neurol; 2003; 53 Suppl 3():S3-12; discussion S12-5. PubMed ID: 12666094
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Drug treatment of Parkinson's disease].
    Jansen EN
    Ned Tijdschr Geneeskd; 1986 May; 130(20):897-9. PubMed ID: 3724862
    [No Abstract]   [Full Text] [Related]  

  • 32. Effects of central dopaminergic stimulation by apomorphine on swallowing disorders in Parkinson's disease.
    Tison F; Wiart L; Guatterie M; Fouillet N; Lozano V; Henry P; Barat M
    Mov Disord; 1996 Nov; 11(6):729-32. PubMed ID: 8914103
    [TBL] [Abstract][Full Text] [Related]  

  • 33. What to do when Sinemet fails: Part one.
    Klawans HL
    Clin Neuropharmacol; 1984; 7(2):121-33. PubMed ID: 6733692
    [No Abstract]   [Full Text] [Related]  

  • 34. Long-term follow-up (24 months) of quetiapine treatment in drug-induced Parkinson disease psychosis.
    Klein C; Prokhorov T; Miniovich A; Dobronevsky E; Rabey JM
    Clin Neuropharmacol; 2006; 29(4):215-9. PubMed ID: 16855423
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic-rigid syndromes.
    Rich SS; Friedman JH; Ott BR
    J Clin Psychiatry; 1995 Dec; 56(12):556-9. PubMed ID: 8530331
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of quetiapine on psychosis and motor function in parkinsonian patients with and without dementia.
    Reddy S; Factor SA; Molho ES; Feustel PJ
    Mov Disord; 2002 Jul; 17(4):676-81. PubMed ID: 12210856
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Value of clozapine in treatment of psychotic disorder in Parkinson disease].
    Abbar M; Courtet P; Castelnau D
    Encephale; 1996; 22(1):53-63. PubMed ID: 8681876
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Between Scylla and Charybdis: drug-induced psychosis in patients with Parkinson disease].
    Kuiper MA; Zwaan WA; Wolters EC
    Ned Tijdschr Geneeskd; 1994 Jul; 138(27):1353-7. PubMed ID: 8035892
    [No Abstract]   [Full Text] [Related]  

  • 39. [Ziprasidone in Parkinsonian dopamine psychosis].
    Durán-Ferreras E; Alvarez-López M; García-Moreno JM; Chacón J
    Rev Neurol; 2008 Apr 16-30; 46(8):476-80. PubMed ID: 18428105
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Renaissance of amantadine in the treatment of Parkinson's disease.
    Blanchet PJ; Metman LV; Chase TN
    Adv Neurol; 2003; 91():251-7. PubMed ID: 12442683
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.